Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis

Hemodialysis International

Volumn 12, Issue SUPPL. 2, 2008, Pages

  Nakamoto, Hidetomo ^a   Mimura, Taku ^b   Honda, Nobuko ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b Tamura Memorial Hospital   (Japan)

Author keywords

Anemia; Erythropoietin resistance; Hemodialysis; Juzen taiho to (TJ 48)

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; SHI QUAN DA BU TANG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANEMIA; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

ADMINISTRATION, ORAL; AGED; ANEMIA; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MITOGENS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 53349101229     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2008.00317.x     Document Type: Conference Paper

References (22)

1. Sho Y, Fujisaki K, Sakashita H, et al. Orally administrated Kampo medicine, Juzen-taiho-to, ameliorates anemia during interferon plus ribavirin therapy in patients with chronic hepatitis C. J Gastroenterol. 2004; 39:1202-1204.
2. Kogure T, Hoshino A, Ito K, et al. Beneficial effect of complementary alternative medicine on lymphedema with rheumatoid arthritis. Mod Rheumatol. 2005; 15:445-449.
3. Maruyama H, Kawamura H, Takemoto N, Komatsu Y, Aburada M, Hosoya E. Effect of Juzen-taiho-to on phagocytosis. Jpn J Inflamm. 1998; 8:461-465 (in Japanese).
4. Haranaka K, Satomi N, Sakurai A, Haranaka R, Okada N, Kobayashi M. Antitumor activities and tumor necrosis factor producibility of traditional Chinese medicines and crude drugs. Cancer Immunol Immunother. 1985; 20:1-5.
5. Hamada M, Fujii Y, Yamamoto H, et al. Effect of a kampo medicine, zyuzentaihotô, on the immune reactivity of tumor-bearing mice. J Ethnopharmacol. 1988; 24:311-320.
6. Tagami K, Niwa K, Lian Z, Gao J, Mori H, Tamaya T. Preventive effect of Juzen-taiho-to on endometrial carcinogenesis in mice is based on Shimotsu-to constituent. Biol Pharm Bull. 2004; 27:156-161.
7. Hisha H, Yamada H, Sakurai M, et al. Isolation and identification of hematopoietic stem cell stimulating substances from Kampo (Japanese herbal) medicine, Juzen-taiho-to. Blood. 1997; 90:1022-1030.
8. Xue JL, St Peter WL, Ebben JP, Everson SE, Collins AJ. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis. 2002; 40:1153-1161.
9. Paganini EP. Overview of anemia associated with chronic renal disease: Primary and secondary mechanisms (review). Semin Nephrol. 1989; 9(Suppl 1):3-8.
10. Macdougall IC, Cooper AC. Erythropoietin resistance: The role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2002; 17(Suppl 11):39-43.
11. Neves PL, Triviño J, Casaubon F, et al. Elderly patients on chronic hemodialysis: Effect of the secondary hyperparathyroidism on the hemoglobin level. Int Urol Nephrol. 2002; 34:147-149.
12. Abu-Alfa AK, Cruz D, Perazella MA, Mahnensmith RL, Simon D, Bia MJ. ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. Am J Kidney Dis. 2000; 35:1076-1082.
13. Odabas AR, Cetinkaya R, Selcuk Y, Keles S, Bilen H. The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis. Panminerva Med. 2003; 45:59-62.
14. Nakamoto H, Kanno Y, Okada H, Suzuki H. Erythropoietin resistance in patients on continuous ambulatory peritoneal dialysis. Adv Perit Dial. 2004; 20:111-116.
15. Maitra S, Burkart J, Fine A, et al. Patients on chronic peritoneal dialysis for ten years or more in North America. Perit Dial Int. 2000; 20(Suppl 2):S127-S133.
16. Del Vecchio L, Pozzoni P, Andrulli S, Locatelli F. Inflammation and resistance to treatment with recombinant human erythropoietin. J Ren Nutr. 2005; 15:137-141.
17. Tahara E, Satoh T, Tiorizuka K, et al. Effect of Shimotsu-to (a Kampo medicine, Si-Wu-Tang) and its constituents on triphasic skin reaction in passively sensitized mice. J Ethnopharmacol. 1999; 68:219-228.
18. Zee-Cheng RK. Shi-quan-da-bu-tang (ten significant tonic decoction), SQT. A potent Chinese biological response modifier in cancer immunotherapy, potentiation and detoxification of anticancer drugs. Methods Find Exp Clin Pharmacol. 1992; 14:725-736.
19. Dai Y, Kato M, Takeda K, et al. T-cell-immunity-based inhibitory effects of orally administered herbal medicine Juzen-taiho-to on the growth of primarily developed melanocytic tumors in RET-transgenic mice. J Invest Dermatol. 2001; 117:694-701.
20. Sakai J. A Kampo medicine "Juzen-taiho-to" - prevention of malignant progression and metastasis of tumor cells and the mechanism of action. Biol Pharm Bull. 2000; 23:677-688.
21. Chino A, Sakurai H, Choo MK, et al. Juzentaihoto, a Kampo medicine, enhances IL-12 production by modulating Toll-like receptor 4 signaling pathways in murine peritoneal exudate macrophages. Int Immunopharmacol. 2005; 5:871-872.
22. Kiyohara H, Nagai T, Munakata K, et al. Stimulating effect of Japanese herbal (kampo) medicine, hochuekkito on upper respiratory mucosal immune system. Evid Based Complement Alternat Med. 2006; 3:459-467.